This Is What Barrons Said On Pfizer, Norcartis and JNJ Being Big Shareholders LINK
The total annual cost of treating heart failure today is $39 billion in the U.S. alone. By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significance of CUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transaction, if results are promising for future success
Updates on Biotech Stocks Celladon Corporation ( CLDN )Top line data due out on Systolic Heart Faiure.They have FDA Fast Track and Breakthrough Therapy Designations. We think this stock couldsee $80.
google it in black and white
Follow the bull calls - Means someone knows something or there's good things happening with this drug. I believe it's that JNJ going full force with Imetelstat . Which means GERN is extremely undervalued and will see nice gains from here or JNJ could buy them out.
Feb 17, 2015 HACKSELL ULIOfficer 30,000 Indirect Automatic Sale at $34.30 per share. 1,029,000
Feb 17, 2015 RASMUSSEN TORSTENDirector 19,847 Indirect Automatic Sale at $35.05 per share. 695,637